{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:06:04Z","timestamp":1790456764838,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ejca.2022.05.007","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T17:20:52Z","timestamp":1656436852000},"page":"259-268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study"],"prefix":"10.1016","volume":"171","author":[{"given":"Caroline","family":"Even","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-9776","authenticated-orcid":false,"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Burge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-9471","authenticated-orcid":false,"given":"Hyun C.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6554-5488","authenticated-orcid":false,"given":"Marwan","family":"Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Norwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.05.007_bib1","series-title":"World Health Organization classification of tumours. Pathology & genetics: Head and neck tumours","article-title":"Tumours of the salivary glands: Introduction","author":"Eveson","year":"2005"},{"key":"10.1016\/j.ejca.2022.05.007_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"10.1016\/j.ejca.2022.05.007_bib3","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1245\/s10434-016-5356-3","article-title":"Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland","volume":"23","author":"Nam","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib4","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/cncr.32792","article-title":"Distant metastasis of salivary gland cancer: incidence, management, and outcomes","volume":"126","author":"Mimica","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.05.007_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005964","article-title":"Risk factors and prognosis for salivary gland adenoid cystic carcinoma in southern China: a 25-year retrospective study","volume":"96","author":"Ouyang","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejca.2022.05.007_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.oraloncology.2008.10.010","article-title":"Survival from salivary glands adenoid cystic carcinoma in European populations","volume":"45","author":"Ciccolallo","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib7","unstructured":"American Cancer Society. Survival rates for salivary gland cancer. Available at: https:\/\/www.cancer.org\/cancer\/salivary-gland-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed August 11, 2021."},{"issue":"suppl 1","key":"10.1016\/j.ejca.2022.05.007_bib8","first-page":"E2041","article-title":"High-grade histology as predictor of early distant metastases and decreased disease-free survival in salivary gland cancer irrespective of tumor subtype","volume":"38","author":"Haderlein","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2022.05.007_bib9","article-title":"NCCN clinical practice guidelines in Oncology (NCCN guidelines)","year":"2021","journal-title":"Head and neck cancers"},{"key":"10.1016\/j.ejca.2022.05.007_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/oxfordjournals.annonc.a010684","article-title":"Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients","volume":"7","author":"Licitra","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.05.007_bib12","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/COC.0000000000000429","article-title":"Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study","volume":"41","author":"Cohen","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib16","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1200\/JCO.2019.37.15_suppl.6083","article-title":"NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent\/metastatic (R\/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group","volume":"37","author":"Fayette","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib17","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1200\/JCO.2019.37.15_suppl.6084","article-title":"A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic adenoid cystic carcinoma (R\/M ACC)","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib18","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1200\/JCO.2021.39.15_suppl.6002","article-title":"A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent\/metastatic salivary gland cancers (R\/M SGCs)","volume":"39","author":"Burman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.007_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00262-020-02730-5","article-title":"Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors","volume":"70","author":"Papadopoulos","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2022.05.007_bib20","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.2147\/CMAR.S151023","article-title":"Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data","volume":"11","author":"du Rusquec","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2022.05.007_bib21","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.05.007_bib22","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922002854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:38:18Z","timestamp":1760733498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922002854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":22,"alternative-id":["S0959804922002854"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.007","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}